25 XP   0   0   10

Hangzhou Tigermed Consulting
Buy, Hold or Sell?

Let's analyse Hangzhou Tigermed Consulting together

PenkeI guess you are interested in Hangzhou Tigermed Consulting. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hangzhou Tigermed Consulting. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hangzhou Tigermed Consulting

I send you an email if I find something interesting about Hangzhou Tigermed Consulting.

Quick analysis of Hangzhou Tigermed Consulting (30 sec.)










What can you expect buying and holding a share of Hangzhou Tigermed Consulting? (30 sec.)

How much money do you get?

How much money do you get?
¥0.09
When do you have the money?
1 year
How often do you get paid?
97.5%

What is your share worth?

Current worth
¥28.03
Expected worth in 1 year
¥30.06
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
¥2.67
Return On Investment
5.2%

For what price can you sell your share?

Current Price per Share
¥51.73
Expected price per share
¥47.85 - ¥73.19
How sure are you?
50%

1. Valuation of Hangzhou Tigermed Consulting (5 min.)




Live pricePrice per Share (EOD)

¥51.73

Intrinsic Value Per Share

¥3.05 - ¥3.20

Total Value Per Share

¥31.08 - ¥31.23

2. Growth of Hangzhou Tigermed Consulting (5 min.)




Is Hangzhou Tigermed Consulting growing?

Current yearPrevious yearGrowGrow %
How rich?$3.3b$3b$301.8m9.1%

How much money is Hangzhou Tigermed Consulting making?

Current yearPrevious yearGrowGrow %
Making money$69.9m$69.3m$632.1k0.9%
Net Profit Margin27.1%28.3%--

How much money comes from the company's main activities?

3. Financial Health of Hangzhou Tigermed Consulting (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#17 / 146

Most Revenue
#44 / 146

Most Profit
#30 / 146

What can you expect buying and holding a share of Hangzhou Tigermed Consulting? (5 min.)

Welcome investor! Hangzhou Tigermed Consulting's management wants to use your money to grow the business. In return you get a share of Hangzhou Tigermed Consulting.

What can you expect buying and holding a share of Hangzhou Tigermed Consulting?

First you should know what it really means to hold a share of Hangzhou Tigermed Consulting. And how you can make/lose money.

Speculation

The Price per Share of Hangzhou Tigermed Consulting is ¥51.73. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hangzhou Tigermed Consulting.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hangzhou Tigermed Consulting, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥28.03. Based on the TTM, the Book Value Change Per Share is ¥0.51 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.16 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hangzhou Tigermed Consulting.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.020.0%0.090.2%0.080.2%0.080.2%0.050.1%
Usd Book Value Change Per Share-0.020.0%0.070.1%0.080.2%0.170.3%0.090.2%
Usd Dividend Per Share0.010.0%0.020.0%0.020.0%0.020.0%0.010.0%
Usd Total Gains Per Share-0.010.0%0.090.2%0.100.2%0.180.4%0.100.2%
Usd Price Per Share7.60-9.74-14.44-14.12-9.68-
Price to Earnings Ratio82.54-38.69-46.85-52.96-104.30-
Price-to-Total Gains Ratio-759.03--122.57-145.32-82.77-238.53-
Price to Book Ratio1.96-2.56-4.17-6.83-13.58-
Price-to-Total Gains Ratio-759.03--122.57-145.32-82.77-238.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.149086
Number of shares139
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.02
Usd Book Value Change Per Share0.070.17
Usd Total Gains Per Share0.090.18
Gains per Quarter (139 shares)12.8325.21
Gains per Year (139 shares)51.30100.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
112394199291
225789217184192
33711714326276293
44915619435369394
56119524543461495
67423429652553596
78627334761645697
89831239870737798
911035144978829899
10123390500879211000

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%46.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%36.04.00.090.0%41.05.00.089.1%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%39.00.01.097.5%44.00.02.095.7%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%37.03.00.092.5%43.03.00.093.5%

Fundamentals of Hangzhou Tigermed Consulting

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-16 14:18:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hangzhou Tigermed Consulting.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hangzhou Tigermed Consulting earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • A Net Profit Margin of 8.4% means that ¥0.08 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hangzhou Tigermed Consulting:

  • The MRQ is 8.4%. The company is making a profit. +1
  • The TTM is 27.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ8.4%TTM27.1%-18.7%
TTM27.1%YOY28.3%-1.2%
TTM27.1%5Y38.8%-11.8%
5Y38.8%10Y28.1%+10.7%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4%-7.2%+15.6%
TTM27.1%-6.3%+33.4%
YOY28.3%1.3%+27.0%
5Y38.8%-2.2%+41.0%
10Y28.1%-1.4%+29.5%
1.1.2. Return on Assets

Shows how efficient Hangzhou Tigermed Consulting is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • 0.5% Return on Assets means that Hangzhou Tigermed Consulting generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hangzhou Tigermed Consulting:

  • The MRQ is 0.5%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.5%TTM1.7%-1.2%
TTM1.7%YOY1.9%-0.2%
TTM1.7%5Y2.8%-1.1%
5Y2.8%10Y2.7%+0.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5%-1.5%+2.0%
TTM1.7%-1.2%+2.9%
YOY1.9%-0.6%+2.5%
5Y2.8%-0.6%+3.4%
10Y2.7%-0.9%+3.6%
1.1.3. Return on Equity

Shows how efficient Hangzhou Tigermed Consulting is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • 0.7% Return on Equity means Hangzhou Tigermed Consulting generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hangzhou Tigermed Consulting:

  • The MRQ is 0.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM2.5%-1.8%
TTM2.5%YOY2.7%-0.2%
TTM2.5%5Y4.2%-1.8%
5Y4.2%10Y3.9%+0.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%-0.5%+1.2%
TTM2.5%-+2.5%
YOY2.7%0.3%+2.4%
5Y4.2%-1.5%+5.7%
10Y3.9%-2.5%+6.4%

1.2. Operating Efficiency of Hangzhou Tigermed Consulting.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hangzhou Tigermed Consulting is operating .

  • Measures how much profit Hangzhou Tigermed Consulting makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hangzhou Tigermed Consulting:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.0%-6.0%
TTM6.0%YOY24.8%-18.8%
TTM6.0%5Y24.9%-18.9%
5Y24.9%10Y14.0%+10.8%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--6.2%+6.2%
TTM6.0%-5.8%+11.8%
YOY24.8%4.8%+20.0%
5Y24.9%1.6%+23.3%
10Y14.0%-2.0%+16.0%
1.2.2. Operating Ratio

Measures how efficient Hangzhou Tigermed Consulting is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 1.47 means that the operating costs are ¥1.47 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hangzhou Tigermed Consulting:

  • The MRQ is 1.474. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.379. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.474TTM1.379+0.095
TTM1.379YOY1.349+0.030
TTM1.3795Y1.307+0.072
5Y1.30710Y0.986+0.321
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4741.310+0.164
TTM1.3791.303+0.076
YOY1.3491.240+0.109
5Y1.3071.270+0.037
10Y0.9861.228-0.242

1.3. Liquidity of Hangzhou Tigermed Consulting.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hangzhou Tigermed Consulting is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 2.74 means the company has ¥2.74 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hangzhou Tigermed Consulting:

  • The MRQ is 2.741. The company is able to pay all its short-term debts. +1
  • The TTM is 2.741. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.741TTM2.741+0.000
TTM2.741YOY3.083-0.342
TTM2.7415Y4.322-1.581
5Y4.32210Y2.276+2.046
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7412.194+0.547
TTM2.7412.366+0.375
YOY3.0832.753+0.330
5Y4.3222.989+1.333
10Y2.2763.000-0.724
1.3.2. Quick Ratio

Measures if Hangzhou Tigermed Consulting is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • A Quick Ratio of 0.31 means the company can pay off ¥0.31 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hangzhou Tigermed Consulting:

  • The MRQ is 0.315. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.422. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.315TTM0.422-0.107
TTM0.422YOY0.804-0.382
TTM0.4225Y0.832-0.410
5Y0.83210Y1.038-0.205
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3151.273-0.958
TTM0.4221.355-0.933
YOY0.8041.563-0.759
5Y0.8321.952-1.120
10Y1.0382.127-1.089

1.4. Solvency of Hangzhou Tigermed Consulting.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hangzhou Tigermed Consulting assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hangzhou Tigermed Consulting to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.18 means that Hangzhou Tigermed Consulting assets are financed with 17.6% credit (debt) and the remaining percentage (100% - 17.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hangzhou Tigermed Consulting:

  • The MRQ is 0.176. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.181. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.176TTM0.181-0.005
TTM0.181YOY0.166+0.015
TTM0.1815Y0.178+0.003
5Y0.17810Y0.205-0.027
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1760.425-0.249
TTM0.1810.411-0.230
YOY0.1660.393-0.227
5Y0.1780.450-0.272
10Y0.2050.448-0.243
1.4.2. Debt to Equity Ratio

Measures if Hangzhou Tigermed Consulting is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 24.9% means that company has ¥0.25 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hangzhou Tigermed Consulting:

  • The MRQ is 0.249. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.257. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.249TTM0.257-0.009
TTM0.257YOY0.231+0.026
TTM0.2575Y0.272-0.015
5Y0.27210Y0.305-0.033
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2490.606-0.357
TTM0.2570.571-0.314
YOY0.2310.606-0.375
5Y0.2720.637-0.365
10Y0.3050.730-0.425

2. Market Valuation of Hangzhou Tigermed Consulting

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hangzhou Tigermed Consulting generates.

  • Above 15 is considered overpriced but always compare Hangzhou Tigermed Consulting to the Diagnostics & Research industry mean.
  • A PE ratio of 82.54 means the investor is paying ¥82.54 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hangzhou Tigermed Consulting:

  • The EOD is 77.679. Based on the earnings, the company is expensive. -2
  • The MRQ is 82.544. Based on the earnings, the company is expensive. -2
  • The TTM is 38.685. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD77.679MRQ82.544-4.865
MRQ82.544TTM38.685+43.859
TTM38.685YOY46.849-8.164
TTM38.6855Y52.957-14.272
5Y52.95710Y104.304-51.347
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD77.679-0.202+77.881
MRQ82.544-0.402+82.946
TTM38.685-0.119+38.804
YOY46.849-0.003+46.852
5Y52.9572.211+50.746
10Y104.3044.907+99.397
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hangzhou Tigermed Consulting:

  • The EOD is 29.928. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 31.802. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is -58.821. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD29.928MRQ31.802-1.874
MRQ31.802TTM-58.821+90.623
TTM-58.821YOY-27.273-31.547
TTM-58.8215Y102.971-161.791
5Y102.97110Y161.748-58.777
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD29.928-0.179+30.107
MRQ31.802-0.417+32.219
TTM-58.821-1.288-57.533
YOY-27.273-2.547-24.726
5Y102.971-1.999+104.970
10Y161.748-2.372+164.120
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hangzhou Tigermed Consulting is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 1.96 means the investor is paying ¥1.96 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Hangzhou Tigermed Consulting:

  • The EOD is 1.846. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.961. Based on the equity, the company is underpriced. +1
  • The TTM is 2.565. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.846MRQ1.961-0.116
MRQ1.961TTM2.565-0.604
TTM2.565YOY4.173-1.609
TTM2.5655Y6.833-4.268
5Y6.83310Y13.581-6.749
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD1.8461.877-0.031
MRQ1.9612.437-0.476
TTM2.5652.235+0.330
YOY4.1733.239+0.934
5Y6.8333.450+3.383
10Y13.5814.040+9.541
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hangzhou Tigermed Consulting compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1120.508-122%0.595-119%1.199-109%0.676-117%
Book Value Per Share--28.03027.590+2%25.087+12%19.069+47%10.739+161%
Current Ratio--2.7412.741+0%3.083-11%4.322-37%2.276+20%
Debt To Asset Ratio--0.1760.181-3%0.166+6%0.178-1%0.205-14%
Debt To Equity Ratio--0.2490.257-3%0.231+8%0.272-9%0.305-18%
Dividend Per Share--0.0400.160-75%0.141-72%0.113-65%0.080-50%
Eps--0.1660.652-74%0.575-71%0.575-71%0.327-49%
Free Cash Flow Per Share--0.4320.240+80%0.260+66%0.238+81%0.174+148%
Free Cash Flow To Equity Per Share--0.4320.423+2%0.579-25%0.957-55%0.689-37%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.203--------
Intrinsic Value_10Y_min--3.049--------
Intrinsic Value_1Y_max--0.963--------
Intrinsic Value_1Y_min--0.946--------
Intrinsic Value_3Y_max--2.404--------
Intrinsic Value_3Y_min--2.305--------
Intrinsic Value_5Y_max--3.255--------
Intrinsic Value_5Y_min--3.064--------
Market Cap38760926476.160-24%47956829553.40061466225690.100-22%91175824552.930-47%86816872512.769-45%57591061501.890-17%
Net Profit Margin--0.0840.271-69%0.283-70%0.388-78%0.281-70%
Operating Margin---0.060-100%0.248-100%0.249-100%0.140-100%
Operating Ratio--1.4741.379+7%1.349+9%1.307+13%0.986+49%
Pb Ratio1.846-6%1.9612.565-24%4.173-53%6.833-71%13.581-86%
Pe Ratio77.679-6%82.54438.685+113%46.849+76%52.957+56%104.304-21%
Price Per Share51.730-6%54.97070.455-22%104.508-47%102.206-46%70.031-22%
Price To Free Cash Flow Ratio29.928-6%31.802-58.821+285%-27.273+186%102.971-69%161.748-80%
Price To Total Gains Ratio-714.292+6%-759.030-122.572-84%145.321-622%82.768-1017%238.527-418%
Quick Ratio--0.3150.422-25%0.804-61%0.832-62%1.038-70%
Return On Assets--0.0050.017-72%0.019-75%0.028-83%0.027-82%
Return On Equity--0.0070.025-72%0.027-74%0.042-84%0.039-82%
Total Gains Per Share---0.0720.668-111%0.736-110%1.312-106%0.755-110%
Usd Book Value--3379482288.4753326515118.489+2%3024696801.477+12%2267001683.293+49%1258195431.538+169%
Usd Book Value Change Per Share---0.0150.070-122%0.082-119%0.166-109%0.093-117%
Usd Book Value Per Share--3.8743.813+2%3.467+12%2.635+47%1.484+161%
Usd Dividend Per Share--0.0050.022-75%0.019-72%0.016-65%0.011-50%
Usd Eps--0.0230.090-74%0.079-71%0.079-71%0.045-49%
Usd Free Cash Flow--52100132.61228907332.350+80%31402418.510+66%28106981.870+85%18415347.291+183%
Usd Free Cash Flow Per Share--0.0600.033+80%0.036+66%0.033+81%0.024+148%
Usd Free Cash Flow To Equity Per Share--0.0600.058+2%0.080-25%0.132-55%0.095-37%
Usd Market Cap5356760039.005-24%6627633844.2808494632390.372-22%12600498953.215-47%11998091781.265-45%7959084699.561-17%
Usd Price Per Share7.149-6%7.5979.737-22%14.443-47%14.125-46%9.678-22%
Usd Profit--20072936.24769958567.124-71%69326372.820-71%65624094.828-69%36942928.127-46%
Usd Revenue--239578202.461255118563.373-6%244803039.249-2%177439380.123+35%112019487.141+114%
Usd Total Gains Per Share---0.0100.092-111%0.102-110%0.181-106%0.104-110%
 EOD+5 -3MRQTTM+13 -22YOY+8 -275Y+12 -2310Y+14 -21

3.2. Fundamental Score

Let's check the fundamental score of Hangzhou Tigermed Consulting based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1577.679
Price to Book Ratio (EOD)Between0-11.846
Net Profit Margin (MRQ)Greater than00.084
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.315
Current Ratio (MRQ)Greater than12.741
Debt to Asset Ratio (MRQ)Less than10.176
Debt to Equity Ratio (MRQ)Less than10.249
Return on Equity (MRQ)Greater than0.150.007
Return on Assets (MRQ)Greater than0.050.005
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Hangzhou Tigermed Consulting based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.957
Ma 20Greater thanMa 5052.703
Ma 50Greater thanMa 10047.613
Ma 100Greater thanMa 20050.978
OpenGreater thanClose51.870
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Interest Income  19,080-3,11915,96135,63851,599-13,39938,200-38,244-45



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets29,680,742
Total Liabilities5,227,180
Total Stockholder Equity21,026,775
 As reported
Total Liabilities 5,227,180
Total Stockholder Equity+ 21,026,775
Total Assets = 29,680,742

Assets

Total Assets29,680,742
Total Current Assets11,344,141
Long-term Assets18,336,601
Total Current Assets
Cash And Cash Equivalents 7,419,992
Short-term Investments 42,138
Net Receivables 1,260,700
Inventory 23,398
Other Current Assets 97,140
Total Current Assets  (as reported)11,344,141
Total Current Assets  (calculated)8,843,368
+/- 2,500,773
Long-term Assets
Property Plant Equipment 1,472,608
Goodwill 2,764,188
Intangible Assets 371,130
Long-term Assets Other 156,896
Long-term Assets  (as reported)18,336,601
Long-term Assets  (calculated)4,764,822
+/- 13,571,780

Liabilities & Shareholders' Equity

Total Current Liabilities4,138,736
Long-term Liabilities1,088,444
Total Stockholder Equity21,026,775
Total Current Liabilities
Short Long Term Debt 1,969,694
Accounts payable 249,308
Other Current Liabilities 18,238
Total Current Liabilities  (as reported)4,138,736
Total Current Liabilities  (calculated)2,237,240
+/- 1,901,496
Long-term Liabilities
Long term Debt 434,223
Capital Lease Obligations Min Short Term Debt423,109
Long-term Liabilities  (as reported)1,088,444
Long-term Liabilities  (calculated)857,332
+/- 231,112
Total Stockholder Equity
Retained Earnings 8,774,795
Total Stockholder Equity (as reported)21,026,775
Total Stockholder Equity (calculated)8,774,795
+/- 12,251,980
Other
Capital Stock872,418
Common Stock Shares Outstanding 872,418
Net Invested Capital 23,430,692
Net Working Capital 7,205,405
Property Plant and Equipment Gross 1,472,608



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302011-12-312010-12-312009-12-31
> Total Assets 
67,388
119,911
186,758
213,917
708,543
732,839
752,424
732,572
753,070
808,010
884,097
882,416
1,203,510
1,357,618
1,152,200
1,148,309
1,395,335
1,610,031
2,065,482
2,141,324
2,137,882
2,388,328
2,459,165
3,239,012
3,386,188
3,583,168
3,934,264
3,955,502
4,077,890
4,279,788
4,403,345
6,420,245
6,310,006
7,532,651
8,242,151
9,267,418
18,829,544
19,506,058
20,281,478
21,220,911
21,955,208
23,741,172
24,803,252
25,703,180
27,140,007
27,446,511
28,172,128
29,666,676
30,072,449
29,680,742
29,680,74230,072,44929,666,67628,172,12827,446,51127,140,00725,703,18024,803,25223,741,17221,955,20821,220,91120,281,47819,506,05818,829,5449,267,4188,242,1517,532,6516,310,0066,420,2454,403,3454,279,7884,077,8903,955,5023,934,2643,583,1683,386,1883,239,0122,459,1652,388,3282,137,8822,141,3242,065,4821,610,0311,395,3351,148,3091,152,2001,357,6181,203,510882,416884,097808,010753,070732,572752,424732,839708,543213,917186,758119,91167,388
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,522,371
1,444,174
1,603,248
1,648,287
3,504,858
3,251,859
3,369,960
3,500,584
3,824,603
12,514,094
11,645,970
11,497,375
11,458,922
10,457,225
10,851,801
10,497,396
10,711,950
11,034,455
11,107,248
11,215,265
11,976,418
11,465,405
11,344,141
11,344,14111,465,40511,976,41811,215,26511,107,24811,034,45510,711,95010,497,39610,851,80110,457,22511,458,92211,497,37511,645,97012,514,0943,824,6033,500,5843,369,9603,251,8593,504,8581,648,2871,603,2481,444,1741,522,371000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
584,863
501,128
704,487
705,258
2,250,449
2,066,735
2,042,306
2,062,159
2,253,095
10,965,557
10,123,891
9,712,470
9,558,961
8,408,147
8,544,356
7,985,048
7,774,935
7,749,593
7,858,140
7,616,131
8,137,911
7,417,101
7,419,992
7,419,9927,417,1018,137,9117,616,1317,858,1407,749,5937,774,9357,985,0488,544,3568,408,1479,558,9619,712,47010,123,89110,965,5572,253,0952,062,1592,042,3062,066,7352,250,449705,258704,487501,128584,863000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,155
0
587
0
603
0
0
0
6,000
6,000
26,000
146,600
91,000
49,680
29,180
36,500
35,569
31,000
24,946
32,841
20,000
25,000
42,138
42,13825,00020,00032,84124,94631,00035,56936,50029,18049,68091,000146,60026,0006,0006,0000006030587019,155000000000000000000000000000
       Net Receivables 
19,202
26,458
49,539
71,313
84,995
94,535
114,604
126,821
111,952
140,470
190,812
219,853
252,410
311,561
334,289
358,279
376,292
421,844
467,364
559,809
578,425
511,653
511,883
557,137
652,228
692,517
804,509
853,237
863,257
838,860
794,249
1,025,603
1,056,733
1,222,009
1,319,569
1,422,189
1,430,030
1,435,170
1,558,218
1,733,199
1,911,519
2,177,383
2,365,164
2,754,884
3,031,968
3,123,389
1,077,375
3,684,667
1,176,009
1,260,700
1,260,7001,176,0093,684,6671,077,3753,123,3893,031,9682,754,8842,365,1642,177,3831,911,5191,733,1991,558,2181,435,1701,430,0301,422,1891,319,5691,222,0091,056,7331,025,603794,249838,860863,257853,237804,509692,517652,228557,137511,883511,653578,425559,809467,364421,844376,292358,279334,289311,561252,410219,853190,812140,470111,952126,821114,60494,53584,99571,31349,53926,45819,202
       Inventory 
0
44
95
94
242
269
140
118
113
355
223
424
240
296
668
272
488
437
810
339
324
60
66
72
62
14
18
1,099
343
519
581
626
689
1,206
2,413
1,296
1,553
4,721
5,263
5,525
5,887
6,095
7,642
16,965
35,093
22,204
23,127
26,535
27,239
23,398
23,39827,23926,53523,12722,20435,09316,9657,6426,0955,8875,5255,2634,7211,5531,2962,4131,2066896265815193431,0991814627266603243398104374882726682962404242233551131181402692429495440
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,755,058
2,915,387
3,058,147
4,162,691
4,741,567
5,442,815
6,315,450
7,860,088
8,784,103
9,761,988
11,497,983
12,889,371
14,305,856
14,991,230
16,105,552
16,339,262
16,956,863
17,690,257
18,607,044
18,336,601
18,336,60118,607,04417,690,25716,956,86316,339,26216,105,55214,991,23014,305,85612,889,37111,497,9839,761,9888,784,1037,860,0886,315,4505,442,8154,741,5674,162,6913,058,1472,915,3872,755,058000000000000000000000000000000
       Property Plant Equipment 
17,325
16,473
27,794
28,406
39,621
56,602
51,003
63,824
62,064
81,064
79,600
82,988
126,757
150,542
153,037
167,151
180,060
194,036
183,059
194,607
193,122
200,325
208,300
206,299
212,283
201,959
208,424
258,011
269,851
254,889
292,647
346,038
361,818
425,812
565,304
578,296
599,078
682,669
743,400
864,916
1,035,802
1,123,377
1,151,158
1,242,505
1,308,927
1,326,025
1,325,984
1,371,295
1,432,293
1,472,608
1,472,6081,432,2931,371,2951,325,9841,326,0251,308,9271,242,5051,151,1581,123,3771,035,802864,916743,400682,669599,078578,296565,304425,812361,818346,038292,647254,889269,851258,011208,424201,959212,283206,299208,300200,325193,122194,607183,059194,036180,060167,151153,037150,542126,75782,98879,60081,06462,06463,82451,00356,60239,62128,40627,79416,47317,325
       Goodwill 
0
0
0
0
0
0
0
0
0
0
17,957
39,299
280,254
338,961
341,212
341,212
341,212
469,661
553,999
611,281
611,281
602,161
602,161
1,059,316
1,058,119
1,049,027
1,049,027
1,049,027
1,051,892
1,032,927
1,014,970
1,014,970
1,100,714
1,157,831
1,363,124
1,354,681
1,525,236
1,444,518
1,445,416
1,463,188
1,887,491
1,778,947
2,220,299
2,347,880
2,502,677
2,485,017
2,495,839
2,549,178
2,833,171
2,764,188
2,764,1882,833,1712,549,1782,495,8392,485,0172,502,6772,347,8802,220,2991,778,9471,887,4911,463,1881,445,4161,444,5181,525,2361,354,6811,363,1241,157,8311,100,7141,014,9701,014,9701,032,9271,051,8921,049,0271,049,0271,049,0271,058,1191,059,316602,161602,161611,281611,281553,999469,661341,212341,212341,212338,961280,25439,29917,9570000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,073,059
1,248,847
1,325,121
1,392,332
1,483,436
1,514,652
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,514,6521,483,4361,392,3321,325,1211,248,8471,073,059000000000000000000000000000
       Intangible Assets 
121
353
1,284
20,238
21,700
2,417
20,785
5,607
22,108
4,288
29,407
59,069
300,309
357,988
359,705
353,935
353,542
483,278
567,224
624,577
625,573
615,436
614,903
1,074,858
1,072,814
1,065,717
1,064,955
16,296
14,850
27,820
28,615
13,449
33,411
96,449
93,347
96,412
83,490
141,755
136,489
130,855
121,026
250,635
261,715
289,549
312,543
338,118
335,651
332,425
313,053
371,130
371,130313,053332,425335,651338,118312,543289,549261,715250,635121,026130,855136,489141,75583,49096,41293,34796,44933,41113,44928,61527,82014,85016,2961,064,9551,065,7171,072,8141,074,858614,903615,436625,573624,577567,224483,278353,542353,935359,705357,988300,30959,06929,4074,28822,1085,60720,7852,41721,70020,2381,284353121
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,510
1,362,510
10,489
11,123
8,723
14,323
399,936
110,484
44,387
68,105
17,641
101,605
129,144
66,615
77,056
62,564
49,931
29,351
17,343
156,896
156,89617,34329,35149,93162,56477,05666,615129,144101,60517,64168,10544,387110,484399,93614,3238,72311,12310,4891,362,5103,510000000000000000000000000000000
> Total Liabilities 
23,130
24,123
40,732
36,302
35,621
38,519
35,419
32,704
31,671
52,866
97,680
105,078
372,273
440,720
220,660
197,186
400,419
544,119
503,797
562,087
527,935
548,544
506,561
604,131
718,436
764,177
968,237
924,461
938,325
1,245,629
1,287,776
1,658,964
1,310,867
2,011,003
2,382,065
2,624,077
1,303,337
1,647,584
1,771,231
1,973,942
2,354,551
3,135,974
3,629,856
4,206,272
4,945,848
4,765,480
4,853,583
5,708,826
5,521,216
5,227,180
5,227,1805,521,2165,708,8264,853,5834,765,4804,945,8484,206,2723,629,8563,135,9742,354,5511,973,9421,771,2311,647,5841,303,3372,624,0772,382,0652,011,0031,310,8671,658,9641,287,7761,245,629938,325924,461968,237764,177718,436604,131506,561548,544527,935562,087503,797544,119400,419197,186220,660440,720372,273105,07897,68052,86631,67132,70435,41938,51935,62136,30240,73224,12323,130
   > Total Current Liabilities 
23,131
23,248
38,158
35,077
34,391
38,519
35,419
32,704
31,671
52,866
97,680
105,078
367,838
386,769
166,326
142,007
329,752
471,244
429,941
467,896
434,085
435,783
392,652
492,147
604,797
715,491
921,718
898,891
915,607
1,208,642
1,227,608
1,556,994
1,125,069
1,790,692
1,923,941
2,172,501
899,517
1,139,339
1,342,508
1,450,722
1,711,731
2,412,714
2,984,318
3,434,473
4,058,716
3,729,567
3,796,995
4,633,251
4,272,088
4,138,736
4,138,7364,272,0884,633,2513,796,9953,729,5674,058,7163,434,4732,984,3182,412,7141,711,7311,450,7221,342,5081,139,339899,5172,172,5011,923,9411,790,6921,125,0691,556,9941,227,6081,208,642915,607898,891921,718715,491604,797492,147392,652435,783434,085467,896429,941471,244329,752142,007166,326386,769367,838105,07897,68052,86631,67132,70435,41938,51934,39135,07738,15823,24823,131
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,472
0
18,302
669,094
769,094
451,894
863,772
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000863,772451,894769,094669,09418,302033,472000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,472
0
18,302
669,094
769,094
451,894
863,772
983,516
1,251,779
0
0
0
0
300,000
492,320
1,062,059
1,760,905
2,100,268
1,848,658
2,082,586
2,363,113
2,533,838
1,969,694
1,969,6942,533,8382,363,1132,082,5861,848,6582,100,2681,760,9051,062,059492,320300,00000001,251,779983,516863,772451,894769,094669,09418,302033,472000000000000000000000000000
       Accounts payable 
400
39
1,577
11,394
13,003
11,650
11,047
5,773
2,221
14,046
6,023
9,301
14,719
17,165
31,711
8,627
10,183
10,115
14,859
15,186
18,904
15,483
7,985
3,588
25,201
23,956
24,250
20,901
42,071
43,081
24,232
20,921
34,191
75,191
62,986
60,388
61,405
101,295
81,784
122,661
126,129
147,867
177,955
162,759
193,029
157,958
175,982
174,397
168,544
249,308
249,308168,544174,397175,982157,958193,029162,759177,955147,867126,129122,66181,784101,29561,40560,38862,98675,19134,19120,92124,23243,08142,07120,90124,25023,95625,2013,5887,98515,48318,90415,18614,85910,11510,1838,62731,71117,16514,7199,3016,02314,0462,2215,77311,04711,65013,00311,3941,57739400
       Other Current Liabilities 
22,731
23,209
36,581
23,683
21,388
26,869
24,372
26,931
29,450
38,820
42,448
46,525
79,457
97,368
131,616
133,381
139,026
201,731
151,325
247,532
265,182
245,549
254,993
298,988
314,780
432,090
482,626
423,201
499,434
455,677
54,755
42,822
35,435
662,524
777,562
710,060
684,579
803,108
1,190,829
1,110,579
1,109,819
1,347,334
1,593,767
1,153,089
1,500,062
23,730
52,089
1,662,746
47,523
18,238
18,23847,5231,662,74652,08923,7301,500,0621,153,0891,593,7671,347,3341,109,8191,110,5791,190,829803,108684,579710,060777,562662,52435,43542,82254,755455,677499,434423,201482,626432,090314,780298,988254,993245,549265,182247,532151,325201,731139,026133,381131,61697,36879,45746,52542,44838,82029,45026,93124,37226,86921,38823,68336,58123,20922,731
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60,168
101,970
185,798
220,311
458,124
451,576
403,820
508,245
428,724
523,220
642,820
723,260
645,538
771,800
887,132
1,035,913
1,056,588
1,075,576
1,249,128
1,088,444
1,088,4441,249,1281,075,5761,056,5881,035,913887,132771,800645,538723,260642,820523,220428,724508,245403,820451,576458,124220,311185,798101,97060,168000000000000000000000000000000
       Other Liabilities 
0
875
2,574
1,225
1,230
0
0
0
0
0
0
0
4,436
42,616
50,376
39,388
59,063
40,114
56,802
65,704
76,993
63,585
91,167
62,348
57,701
3,664
0
3,560
69
17,691
13,465
10,390
10,450
66,061
77,722
72,249
166,664
229,223
145,678
199,334
267,633
316,421
247,212
326,158
311,169
302,296
0
333,901
0
0
00333,9010302,296311,169326,158247,212316,421267,633199,334145,678229,223166,66472,24977,72266,06110,45010,39013,46517,691693,56003,66457,70162,34891,16763,58576,99365,70456,80240,11459,06339,38850,37642,6164,43600000001,2301,2252,5748750
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,866
9,118
9,436
8,947
8,229
16,812
19,814
18,646
18,087
24,535
33,428
32,038
33,307
38,066
35,197
38,435
41,423
165,349
211,038
0
200,509
0
0
00200,5090211,038165,34941,42338,43535,19738,06633,30732,03833,42824,53518,08718,64619,81416,8128,2298,9479,4369,1188,866000000000000000000000000000
> Total Stockholder Equity
42,372
93,370
141,161
173,368
668,698
690,059
711,969
693,517
714,647
743,975
774,477
763,101
797,566
863,542
883,901
890,545
927,248
1,002,355
1,501,598
1,512,161
1,533,249
1,626,818
1,672,067
2,351,104
2,377,791
2,503,536
2,639,496
2,672,147
2,770,812
2,668,584
2,751,436
3,670,954
3,864,272
4,225,458
4,519,765
5,185,695
15,990,361
16,118,568
16,423,147
17,011,686
17,183,367
18,123,626
18,404,968
18,654,562
19,191,150
19,583,022
20,145,013
20,586,104
21,059,878
21,026,775
21,026,77521,059,87820,586,10420,145,01319,583,02219,191,15018,654,56218,404,96818,123,62617,183,36717,011,68616,423,14716,118,56815,990,3615,185,6954,519,7654,225,4583,864,2723,670,9542,751,4362,668,5842,770,8122,672,1472,639,4962,503,5362,377,7912,351,1041,672,0671,626,8181,533,2491,512,1611,501,5981,002,355927,248890,545883,901863,542797,566763,101774,477743,975714,647693,517711,969690,059668,698173,368141,16193,37042,372
   Common Stock
30,000
40,000
40,000
40,000
53,400
53,400
53,400
106,800
106,800
106,800
106,800
213,600
213,600
215,019
215,019
430,598
430,598
433,316
470,741
471,301
471,301
474,865
474,865
500,177
500,177
500,177
500,177
500,177
500,177
500,177
500,177
500,177
749,626
749,508
749,468
749,456
872,580
872,484
872,484
872,467
872,391
872,438
872,438
872,418
872,418
872,418
0
872,418
0
0
00872,4180872,418872,418872,418872,438872,438872,391872,467872,484872,484872,580749,456749,468749,508749,626500,177500,177500,177500,177500,177500,177500,177500,177500,177474,865474,865471,301471,301470,741433,316430,598430,598215,019215,019213,600213,600106,800106,800106,800106,80053,40053,40053,40040,00040,00040,00030,000
   Retained Earnings 
2,374
25,356
68,789
97,150
115,168
130,626
152,549
134,164
155,232
173,912
221,178
205,922
236,521
277,198
313,078
310,119
344,702
390,472
429,676
421,550
443,067
484,050
527,432
603,680
634,394
735,046
830,951
841,175
940,443
1,094,706
1,156,210
1,189,469
1,365,475
1,934,517
2,189,486
2,725,066
3,044,281
3,475,665
3,931,145
4,468,908
4,994,994
6,088,107
6,606,524
6,847,648
7,260,303
7,662,196
7,838,790
8,574,811
8,674,217
8,774,795
8,774,7958,674,2178,574,8117,838,7907,662,1967,260,3036,847,6486,606,5246,088,1074,994,9944,468,9083,931,1453,475,6653,044,2812,725,0662,189,4861,934,5171,365,4751,189,4691,156,2101,094,706940,443841,175830,951735,046634,394603,680527,432484,050443,067421,550429,676390,472344,702310,119313,078277,198236,521205,922221,178173,912155,232134,164152,549130,626115,16897,15068,78925,3562,374
   Capital Surplus 00000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,624
12,226
-822
-1,631
2,980
19,528
26,299
39,656
40,401
-35,794
-92,013
-89,734
-126,131
-113,789
-155,993
-156,538
-13,975
108,969
0
0
135,422
0
0
00135,42200108,969-13,975-156,538-155,993-113,789-126,131-89,734-92,013-35,79440,40139,65626,29919,5282,980-1,631-82212,2265,624000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue7,384,039
Cost of Revenue-4,535,511
Gross Profit2,848,5292,848,529
 
Operating Income (+$)
Gross Profit2,848,529
Operating Expense-5,628,083
Operating Income1,755,957-2,779,554
 
Operating Expense (+$)
Research Development261,555
Selling General Administrative447,246
Selling And Marketing Expenses0
Operating Expense5,628,083708,801
 
Net Interest Income (+$)
Interest Income229,849
Interest Expense-119,897
Other Finance Cost-4,237
Net Interest Income105,715
 
Pretax Income (+$)
Operating Income1,755,957
Net Interest Income105,715
Other Non-Operating Income Expenses0
Income Before Tax (EBT)2,488,5331,755,957
EBIT - interestExpense = -119,897
2,024,850
2,144,747
Interest Expense119,897
Earnings Before Interest and Taxes (EBIT)02,608,430
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax2,488,533
Tax Provision-338,606
Net Income From Continuing Ops2,149,9272,149,927
Net Income2,024,850
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-105,715
 

Technical Analysis of Hangzhou Tigermed Consulting
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hangzhou Tigermed Consulting. The general trend of Hangzhou Tigermed Consulting is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hangzhou Tigermed Consulting's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hangzhou Tigermed Consulting.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 72.16 < 72.52 < 73.19.

The bearish price targets are: 49.67 > 48.51 > 47.85.

Tweet this
Hangzhou Tigermed Consulting Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hangzhou Tigermed Consulting. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hangzhou Tigermed Consulting Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hangzhou Tigermed Consulting. The current macd is 1.61990264.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hangzhou Tigermed Consulting price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Hangzhou Tigermed Consulting. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Hangzhou Tigermed Consulting price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hangzhou Tigermed Consulting Daily Moving Average Convergence/Divergence (MACD) ChartHangzhou Tigermed Consulting Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hangzhou Tigermed Consulting. The current adx is 28.76.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hangzhou Tigermed Consulting shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Hangzhou Tigermed Consulting Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hangzhou Tigermed Consulting. The current sar is 58.72.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hangzhou Tigermed Consulting Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hangzhou Tigermed Consulting. The current rsi is 49.96. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Hangzhou Tigermed Consulting Daily Relative Strength Index (RSI) ChartHangzhou Tigermed Consulting Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hangzhou Tigermed Consulting. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hangzhou Tigermed Consulting price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hangzhou Tigermed Consulting Daily Stochastic Oscillator ChartHangzhou Tigermed Consulting Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hangzhou Tigermed Consulting. The current cci is -13.65018683.

Hangzhou Tigermed Consulting Daily Commodity Channel Index (CCI) ChartHangzhou Tigermed Consulting Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hangzhou Tigermed Consulting. The current cmo is -10.61909329.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hangzhou Tigermed Consulting Daily Chande Momentum Oscillator (CMO) ChartHangzhou Tigermed Consulting Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hangzhou Tigermed Consulting. The current willr is -77.58433079.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hangzhou Tigermed Consulting is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hangzhou Tigermed Consulting Daily Williams %R ChartHangzhou Tigermed Consulting Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hangzhou Tigermed Consulting.

Hangzhou Tigermed Consulting Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hangzhou Tigermed Consulting. The current atr is 2.90455385.

Hangzhou Tigermed Consulting Daily Average True Range (ATR) ChartHangzhou Tigermed Consulting Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hangzhou Tigermed Consulting. The current obv is -84,724,829.

Hangzhou Tigermed Consulting Daily On-Balance Volume (OBV) ChartHangzhou Tigermed Consulting Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hangzhou Tigermed Consulting. The current mfi is 54.60.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Hangzhou Tigermed Consulting Daily Money Flow Index (MFI) ChartHangzhou Tigermed Consulting Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hangzhou Tigermed Consulting.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Hangzhou Tigermed Consulting Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hangzhou Tigermed Consulting based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.957
Ma 20Greater thanMa 5052.703
Ma 50Greater thanMa 10047.613
Ma 100Greater thanMa 20050.978
OpenGreater thanClose51.870
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hangzhou Tigermed Consulting with someone you think should read this too:
  • Are you bullish or bearish on Hangzhou Tigermed Consulting? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hangzhou Tigermed Consulting? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hangzhou Tigermed Consulting

I send you an email if I find something interesting about Hangzhou Tigermed Consulting.


Comments

How you think about this?

Leave a comment

Stay informed about Hangzhou Tigermed Consulting.

Receive notifications about Hangzhou Tigermed Consulting in your mailbox!